Printer Friendly

Articles from M2 Pharma (July 24, 2019)

1-18 out of 18 article(s)
Title Author Type Words
Acadia Pharmaceuticals reveals top-line results from Pimavanserin Phase three enhance study. 249
Banner Life Sciences Enrolls First Subject in Randomised, Double-Blind Head-to-Head Study of Bafiertam and Tecfidera for Comparative Assessment of GI Tolerability. 379
Baxter International's Myxredlin approved by US FDA. 214
BlueWillow Biologics wins US patent for intranasal genital herpes protection. 240
Camurus announces receipt of positive outcome of US court proceeding for final approval of Brixadi. 466
Crescendo Biologics' Second Oncology-targeted Humabody Licensed by Takeda. 338
Dalent Medical announces USD1.5m from financing round plus granted patent for the Sinusleeve balloon. 149
Episurf Medical approved for a new European patent. 148
ImaginAb begins Phase II clinical trial of 89Zr-Df-IAB22M2C at Dana-Farber Cancer Institute. 232
Immix announces FDA authorisation letter to expand IMX-110 clinical trial to the US under US IND. 285
Iveric bio Advances LCA10 Minigene Programme and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Programme. 565
LifeSpan BioSciences Releases PathPlus Immunohistochemistry Antibodies for Cancer Targets. 401
Novadoz Pharmaceuticals awarded US FDA approval for generic Pregabalin capsules. 169
Pack Health partners with Glooko Partner to get deeper insight of blood glucose trends in diabetic patients. 203
Sandoz enrols first patient in osteoporosis biosimilar drug trial. 218
Tivic Health announces USD8m from Series Seed Round. 190
Uman Diagnostics signs strategic License and Supply Agreement with Bio-Techne. 132
US FDA authorises Immix Biopharma to proceed with IMX-110 phase 1b/2a clinical trial expansion. 231

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |